Blau Farmacêutica - Public Comps and Valuation Multiples

Blau Farmacêutica Overview

About Blau Farmacêutica

Blau Farmaceutica SA is engaged in the manufacturing, development and commercialization of complex private-label drugs for the institutional segment. The Company’s business activities cover institutional and retail segments, and are divided into four units: 1) Biologicals are a heterogeneous class of products that can be produced using raw materials from biological materials and biotechnological procedures. 2) Oncology line is made up of oral and injectable drugs intended for treating cancer, which encompasses a number of therapeutic classes. 3) Specialties line is made up of products that are used in the hospital’s daily routine, in the specialized treatments for infectious diseases and special treatments. 4) Others consist of prescription and non-prescription over-the-counter drugs.

Founded

1987

HQ

Employees

n/a

Website

blau.com

Sectors

Biopharmaceuticals
Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $334M

LTM EBITDA $84.8M

EV

$494M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Blau Farmacêutica Financials

As of August 2025, Blau Farmacêutica reported last 12-month revenue of $334M and EBITDA of $84.8M.

In the same period, Blau Farmacêutica generated $131M in LTM gross profit and $49.0M in net income.

See Blau Farmacêutica valuation multiples based on analyst estimates

Blau Farmacêutica P&L

In the most recent fiscal year, Blau Farmacêutica reported revenue of $324M and EBITDA of $74.2M.

Blau Farmacêutica expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Blau Farmacêutica valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$334M	XXX	$324M	XXX	XXX	XXX
Gross Profit	$131M	XXX	$122M	XXX	XXX	XXX
Gross Margin	39%	XXX	38%	XXX	XXX	XXX
EBITDA	$84.8M	XXX	$74.2M	XXX	XXX	XXX
EBITDA Margin	25%	XXX	23%	XXX	XXX	XXX
EBIT	$73.3M	XXX	$63.1M	XXX	XXX	XXX
EBIT Margin	22%	XXX	19%	XXX	XXX	XXX
Net Profit	$49.0M	XXX	$40.1M	XXX	XXX	XXX
Net Margin	15%	XXX	12%	XXX	XXX	XXX
Net Debt	XXX	XXX	$89.2M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Blau Farmacêutica including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $334M. EBITDA for the last twelve months was $84.8M. In the most recent fiscal year, Blau Farmacêutica achieved $324M in revenue and $74.2M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$334M	Analyst estimates available to subscribers	$324M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$131M	Analyst estimates available to subscribers	$122M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	39.2% gross margin	Analyst estimates available to subscribers	37.5% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$84.8M	Analyst estimates available to subscribers	$74.2M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	25.4% EBITDA margin	Analyst estimates available to subscribers	22.9% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$73.3M	Analyst estimates available to subscribers	$63.1M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	21.9% EBIT margin	Analyst estimates available to subscribers	19.5% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$49.0M	Analyst estimates available to subscribers	$40.1M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	14.6% net profit margin	Analyst estimates available to subscribers	12.4% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$89.2M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Blau Farmacêutica

This financial data table provides comprehensive performance metrics for Blau Farmacêutica, a company based in Brazil. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Blau Farmacêutica generated $334M in revenue over the last twelve months.
The company achieved $84.8M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $131M.
Net income over the last twelve months reached $49.0M.

Fiscal Year Performance

In the most recent fiscal year, Blau Farmacêutica reported $324M in total revenue.
Fiscal year EBITDA was $74.2M.
The company maintained a gross profit margin of 37.5% in the most recent fiscal year.
EBITDA margin for the fiscal year was 22.9%.
Net profit margin reached 12.4% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Blau Farmacêutica. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Blau Farmacêutica Stock Performance

Blau Farmacêutica has current market cap of BRL 2.5B (or $456M), and EV of BRL 2.7B (or $494M).

Market Cap Evolution

Blau Farmacêutica Stock Data

As of September 12, 2025, Blau Farmacêutica's stock price is BRL 14 (or $3).

See Blau Farmacêutica trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$494M	$456M	XXX	XXX	XXX	XXX	$0.27

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Blau Farmacêutica Valuation Multiples

Blau Farmacêutica's trades at 1.5x EV/Revenue multiple, and 6.7x EV/EBITDA.

See valuation multiples for Blau Farmacêutica and 15K+ public comps

Blau Farmacêutica Financial Valuation Multiples

As of September 12, 2025, Blau Farmacêutica has market cap of $456M and EV of $494M.

Equity research analysts estimate Blau Farmacêutica's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Blau Farmacêutica has a P/E ratio of 9.3x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$456M	XXX	$456M	XXX	XXX	XXX
EV (current)	$494M	XXX	$494M	XXX	XXX	XXX
EV/Revenue	1.5x	XXX	1.5x	XXX	XXX	XXX
EV/EBITDA	5.8x	XXX	6.7x	XXX	XXX	XXX
EV/EBIT	6.7x	XXX	7.8x	XXX	XXX	XXX
EV/Gross Profit	3.8x	XXX	n/a	XXX	XXX	XXX
P/E	9.3x	XXX	11.4x	XXX	XXX	XXX
EV/FCF	10.6x	XXX	7.3x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Blau Farmacêutica Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Blau Farmacêutica Margins & Growth Rates

Blau Farmacêutica's last 12 month revenue growth is 10%

Blau Farmacêutica's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.

Blau Farmacêutica's rule of 40 is 40% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Blau Farmacêutica's rule of X is 50% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Blau Farmacêutica and other 15K+ public comps

Blau Farmacêutica Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	10%	XXX	8%	XXX	XXX	XXX
EBITDA Margin	25%	XXX	23%	XXX	XXX	XXX
EBITDA Growth	12%	XXX	10%	XXX	XXX	XXX
Rule of 40	40%	XXX	33%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	50%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	n/a	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	7%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	2%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	18%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial